DYNOGEN ACQUIRES EXCLUSIVE RIGHTS TO PUMOSETRAG.Dynogen Pharmaceuticals, Inc. Waltham, Mass., has acquired an exclusive license to the clinical-stage compound pumosetrag from Mitsubishi Pharma Mitsubishi Pharma Corporation (三菱ウェルファーマ株式会社 Corporation. Pumosetrag was previously studied by Mitsubishi in Phase II clinical trials Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored phase II where it demonstrated favorable safety and pharmacokinetic profiles. Dynogen will be initiating clinical studies with pumosetrag in the gastrointestinal (GI) area beginning in 2005. Financial terms of the deal were not disclosed. In addition to issued patents and pending patent applications covering the composition of matter and its use, Dynogen's license includes exclusive rights to all pre-clinical, clinical and manufacturing data related to pumosetrag. Dynogen had previously filed its own patent application covering use of pumosetrag in treating certain GI disorders with high unmet medical need. Mitsubishi retained rights to the compound in Japan and certain other Asian countries. "The acquisition of pumosetrag is further execution of Dynogen's plan to rapidly and efficiently build a high value drug development portfolio of drug candidates for genitourinary genitourinary /gen·i·to·uri·nary/ (jen?i-to-u´ri-nar-e) pertaining to the genital and urinary organs. gen·i·to·u·ri·nar·y adj. Abbr. and gastrointestinal disorders where there are limited therapeutic options for people suffering from these conditions," commented Lee R. Brettman, MD, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Dynogen. "Pumosetrag is the third promising clinical stage compound to be added to our development portfolio in the two years since the company's inception." "There is a dearth of effective products for the treatment of diseases associated with GI tract dysmotility. The prokinetic properties of pumosetrag position it as a promising new therapy," stated Jan H. Egberts, MD, COO at Dynogen. "We are assessing pumosetrag for clinical development in several functional GI disorders such as irritable bowel syndrome irritable bowel syndrome (IBS), condition characterized by frequently alternating constipation and diarrhea in the absence of any disease process. It is usually accompanied by abdominal pain, especially in the lower left quadrant, bloating, and flatulence. with constipation (IBS-c), and we plan to enter the clinic in 2005," Egberts continued. Pumosetrag will be referred to as DDP (Distributed Data Processing) See distributed processing. DDP - Distributed Data Processing 733 in Dynogen's development pipeline. This is the second clinical stage compound Dynogen has licensed from Mitsubishi. The first, DDP225, was licensed in October 2003 and is currently in clinical studies for irritable bowel syndrome with diarrhea (IBS- d). About Dynogen Pharmaceuticals, Inc. Dynogen is a privately held, neuroscience-based pharmaceutical company focused on genitourinary (GU) and gastrointestinal (GI) disorders. The company is utilizing its knowledge of the nexus between neurology neurology (n  rŏl`əjē, ny–), study of the morphology, physiology, and pathology of the human nervous system. and GU/GI disorders, with predictive pharmacology platforms to rapidly build a high value pipeline of drugs. For more information, visit http://www.dynogen.com. About Mitsubishi Pharma Corporation Mitsubishi Pharma Corporation, a research-driven pharmaceutical company, is the core member in the Group of Mitsubishi Chemical Corporation Mitsubishi Chemical Corporation (三菱化学株式会社 , a leading chemical company in Japan. Formed in 2001 by the merger of Mitsubis hi-Tokyo Pharmaceuticals & Welfide Corporation (formerly Yoshitomi). The company is committed to scientific progress, pharmaceutical advancement and the creation of products that benefit worldwide people's welfare. It s core therapeutic areas are psychiatric and central nervous system diseases, cardiovascular and metabolic diseases metabolic disease, n a disorder that causes dysfunction of the metabolic action of the body, resulting in loss of control of homeostasis. paraneoplastic syndrome , immunological and respiratory diseases, and cancer and hepatic diseases. For more information, visit http://www.m-pharma.co.jp or call 508/647-0209. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion